From creating one monster to killing another, Christoph Waltz’s winter has been a horror show. The 69-year-old Austrian Oscar winner played Henrich Harlander, Victor Frankenstein’s wealthy benefactor, ...

An illustration of an antibody disrupting the binding between a virus particle and a receptor on the edge of a membrane. A drug (orange) blocks the SARS-CoV-2 virus (gold sphere with white protruding ...

GlobalWafers opened $3.5 bln Texas plant last year Chairwoman upbeat on Taiwan-US trade deal Company is a major supplier to TSMC HSINCHU, Taiwan, Jan 21 (Reuters) - Taiwanese silicon wafer ...

This is a column about a helpful trick that will radically improve your memory with minimal effort so you can learn faster. But before I get to the science behind the technique and how it can help ...

The US has announced the Gaza ceasefire is moving to phase two, where “demilitarisation, technocratic governance, and reconstruction” will be the focus. Hamas leaders and representatives of other ...

Edun emphasizes need for sustained, inclusive, job-rich growth Growth forecast at 4.68% for 2026, inflation to average 16.5% Reforms this year to focus on digital revenue collection and pro-poor tax ...

Welcome to the Daily News Brief, CFR’s flagship morning newsletter summarizing the top global news and analysis of the day. “To avoid being bypassed by Israel or shot at by Hamas, any future ...

The United States will push forward with the next phase of its plan for peace in Gaza, moving toward "demilitarization, technocratic governance, and reconstruction," President Donald Trump's special ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — The Food and Drug ...

Fans will be able to apply for single-match tickets based on exact match-ups and teams for group-stage games. High demand continues as the Early Ticket Draw sees inventory snatched up by fans in more ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...